S. Thackwray

Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease

Robert P. Anderson, Glenn O. Brown, A. Coates, 2020, BMC Medicine.

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Bin Zhou, N. Patel, M. Frieman, 2022, The Lancet Infectious Diseases.

Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on gluten‐free diet

Glenn O. Brown, M. Mäki, B. Lebwohl, 2020 .

Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.

J. Andrews, R. Gearry, G. Holtmann, 2023, The lancet. Gastroenterology & hepatology.

Abstract 12594: Pharmacodynamic Effect of ARO-APOC3, an Investigational Hepatocyte-targeted RNA Interference Therapeutic Targeting Apolipoprotein C3, in Patients With Hypertriglyceridemia and Multifactorial Chylomicronemia

S. Melquist, J. Knowles, D. Gaudet, 2020 .

Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial.

S. Shakib, J. Druce, T. Evans, 2022, The Lancet. Infectious diseases.

Topical application of a novel anti-interleukin-17A antibody fragment penetrates psoriatic skin: Results of a randomised, double-blind, placebo-controlled Phase Ib study.

Jun Yu Li, Junlong Wu, H. Reinhart, 2023, Experimental dermatology.

RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia.

C. Ballantyne, S. Thackwray, Ting Chang, 2023, NEJM evidence.